vos badges Fourchette 52 semaines $11–$21 6% of range Note des analystes SELL 7 analysts Objectif de cours $12 +6% upside P/E -168.4 ROE -6.0% Marge nette -14.6%

AMRN Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines

03
Prix $11.79
Capitalisation Boursière (MRQ) $4.95B
P/E (TTM) -168.4
BPA (TTM) $-0.07
Revenu (TTM) $186M
ROE (TTM) -6.0%
Fourchette 52 semaines $11–$21

AMRN Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue

04
fourchette
barres

La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.

Splits d'actions 3
Date ex-dividende Division Type
11 avril 2025 1-for-20 Inverse
18 janvier 2008 1-for-10 Inverse
19 octobre 1998 1-for-10 Inverse

À propos de Amarin Corporation plc - American Depositary Shares Présentation de l'entreprise depuis Wikipedia

05 · wikidata

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.

History

Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.

In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.

Products and development

Vascepa (USA) / Vazkepa (EU)

Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.

Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.

HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.

On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.

Patent disputes

On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.

== Finance ==

Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗

Wikidata ↗

secteurHealthcare industrieBiotechnology employés80 paysIE

Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA

06
Revenu$214M
2016-12-31 → 2025-12-31
BPA$-0.09
2016-12-31 → 2025-12-31
Flux de trésorerie libre·
2016-12-31 → 2020-12-31
Marge nette-14.6%
2016-12-31 → 2025-12-31
Valorisation et Ratios 07–12

Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?

Métrique Tendance sur 5 ans AMRN moyenne 5 ans Médiane des pairs Verdict
P/E (TTM) -168.4moyenne 5 ans ≈591.4 ≈591.4 · ·
P/S (TTM) 26.6moyenne 5 ans ≈22.7 ≈22.7 · ·
P/B (MRQ) 11.2moyenne 5 ans ≈11.3 ≈11.3 · ·
Price / Cash Flow (Cours / Flux de trésorerie) 729.4moyenne 5 ans ≈589.2 ≈589.2 · ·
Cours / Actif net tangible (MRQ) 11.5moyenne 5 ans ≈18.7 ≈18.7 · ·

La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.

valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane

Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats

14
Surprise Moyenne 49.9%
Prochain rapport Oct 27, 2026
PériodeRapportEPS ActualBPA est.Surprise
30 juin 2026 Jul 28, 2026 $-0.02 $-0.01 -96.1%
31 mars 2026 $-0.09 $0.09 -203.8%
31 décembre 2025 $0.01 $0.00 —
30 septembre 2025 $0.08 $-0.58 113.8%
30 juin 2025 $0.66 $-0.18 466.3%
31 mars 2025 $-0.76 $-0.58 -30.7%

Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie

15
Compte de résultat 18
Métrique Tendance 202520242023202220212020201920182017201620152014
Revenue $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Cost of Revenue ····$121M$131M$96M$55M$45M$34M$28M$20M
Gross Profit $121M$81M$166M$242M$462M$483M$334M$175M$136M$96M$54M$34M
R&D Expense $20M$21M$22M$30M$29M$39M$34M$56M$47M$50M$51M$50M
SG&A Expense $115M$152M$200M$304M$408M$463M$324M$227M$135M$111M$101M$79M
Operating Expenses $171M$173M$233M$348M$451M$502M$358M$283M$182M$161M$152M$130M
Operating Income $-50M$-92M$-68M$-106M$11M$-20M$-24M$-108M$-46M$-66M$-98M$-96M
Interest Expense $7.0K$7.0K$8.0K$15.0K$129.0K$3M$7M$9M$10M$19M$20M$19M
Interest Income $11M$13M$12M$3M$1M$5M$8M$1M$429.0K$234.0K$132.0K$96.0K
Other Non-op $3M$1M$2M$-740.0K$-302.0K$104.0K$-75.0K$-326.0K$74.0K$-482.0K$-228.0K$4M
Pretax Income $-36M$-77M$-54M$-104M$11M$-17M$-22M$-116M$-55M$-76M$-118M$-59M
Income Tax $3M$5M$5M$2M$4M$745.0K$164.0K$96.0K$13M$10M$-3M$-3M
Net Income $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
EPS (Basic) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.32
EPS (Diluted) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Shares (Basic) 414,984,000410,937,000407,655,000401,155,000395,992,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,719,000
Shares (Diluted) 414,984,000410,937,000407,655,000401,155,000402,480,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,824,000
EBITDA $-50M$-92M$-68M··$-20M·$-108M$-46M$-66M$-98M$-96M
Bilan 27
Métrique Tendance 202520242023202220212020201920182017201620152014
Cash & Equivalents $135M$121M$199M$218M$219M$187M$645M$249M$74M$98M$107M$120M
Short-term Investments $168M$173M$121M$92M$235M$314M······
Receivables $127M$122M$134M$131M$164M$155M$116M$67M$45M$20M$14M$8M
Inventory $196M$166M$259M$229M$235M$189M$77M$58M$30M$21M$19M$14M
Prepaid Expense $24M$13M$12M$19M$22M$31M$13M$3M$3M$7M$3M$3M
Other Current Assets ···········$3M
Current Assets $650M$595M$725M$689M$879M$879M$855M$378M$153M$146M$144M$145M
PP&E (Net) $12.0K$16.0K$114.0K$874.0K$1M$2M$2M$63.0K$28.0K$78.0K$243.0K$381.0K
PP&E (Gross) $1M$1M$1M$3M$3M$4M$3M$902.0K$844.0K$821.0K$997.0K$969.0K
Accum. Depreciation $1M$1M$1M$2M$2M$2M$1M$839.0K$816.0K$755.0K$754.0K$588.0K
Intangibles $13M$16M$19M$22M$24M$14M$15M$7M$8M$9M$9M$10M
Other Non-current Assets $1M$1M$1M$458.0K$456.0K$432.0K$1M$174.0K$174.0K$741.0K$174.0K$3M
Total Assets $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Accounts Payable $45M$40M$53M$65M$115M$106M$50M$38M$25M$6M$11M$9M
Current Liabilities $194M$180M$259M$259M$371M$307M$242M$157M$109M$76M$51M$40M
Capital Leases $6M$8M$9M$10M$9M$9M$9M·····
Other Non-current Liabilities $11M$12M$9M$8M$8M$6M$4M$11M$1M$710.0K$335.0K$386.0K
Total Liabilities $211M$199M$280M$291M$401M$339M$274M$233M$227M$176M$301M$260M
Long-term Debt ······$50M$80M$92M$94M$92M$105M
Total Debt ·····$0·$80M$93M$101M$106M$105M
Common Stock $310M$305M$303M$299M$294M$290M$269M$247M$209M$207M$150M$143M
Paid-in Capital $1.92B$1.91B$1.90B$1.89B$1.86B$1.82B$1.76B$1.28B$978M···
Retained Earnings $-1.71B$-1.67B$-1.59B$-1.53B$-1.42B$-1.43B$-1.41B$-1.39B$-1.27B$-1.20B$-1.12B$-970M
Treasury Stock $67M$65M$64M$62M$61M$51M$36M$10M$4M$1M$411.0K$217.0K
Stockholders' Equity $459M$486M$552M$595M$667M$628M$608M$152M$-65M$-9M$-129M$-88M
Liabilities + Equity $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Shares Outstanding 416,214,102411,584,851408,824,093408,824,093396,598,008392,538,081360,103,901325,850,013271,022,011269,363,696183,403,263174,590,372
Flux de trésorerie 17
Métrique Tendance 202520242023202220212020201920182017201620152014
D&A ·······$23.0K$62.0K$138.0K$166.0K$198.0K
Stock-based Comp $14M$18M$16M$26M$37M$46M$31M$19M$14M$14M$14M$9M
Deferred Tax ········$11M$9M$-4M$-4M
Amort. of Intangibles $3M$3M$3M$3M$2M$1M$679.0K$646.0K$646.0K$645.0K$646.0K$646.0K
Restructuring $36M$0$11M$14M$14M·······
Operating Cash Flow $7M$-31M$7M$-180M$-67M$-22M$-9M$-95M$-33M$-72M$-84M$-75M
CapEx ·····$252.0K$2M$58.0K$12.0K$21.0K$28.0K·
Investing Cash Flow $9M$-46M$-26M$175M$104M$-377M$-2M$-58.0K$-12.0K$-21.0K··
Net Debt Issued ·····$-50M·$-15M$-3M···
Stock Issued ······$440M$265M·$65M··
Stock Repurchased ··········$194.0K·
Net Stock Activity ·······$265M·$65M$-194.0K·
Financing Cash Flow $-2M$-1M$230.0K$-379.0K$-5M$-59M$410M$271M$8M$63M··
Net Change in Cash $14M$-78M$-18M$-5M$32M$-458M$398M$176M$-25M$-9M$-13M$-72M
Taxes Paid $1M$4M$2M$-2M$4M$-207.0K$-67.0K·····
Free Cash Flow ·····$-22M·$-95M$-33M$-72M$-85M·
Levered FCF ·····$-25M·$-104M$-45M$-93M$-104M·
Rentabilité 8
Métrique Tendance 202520242023202220212020201920182017201620152014
Gross Margin 56.6%35.6%53.9%··78.6%·76.2%75.2%73.6%65.9%62.2%
Operating Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
Net Margin -18.2%-35.9%-19.3%··-2.9%·-50.8%-37.5%-66.4%-140.9%-104.0%
Pretax Margin -16.9%-33.8%-17.5%··-2.8%·-50.8%-30.3%-58.7%-144.7%-109.2%
EBITDA Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
ROA -5.7%-10.8%-6.9%··-1.9%·-42.5%-41.3%-50.8%-66.9%-26.6%
ROE -8.4%-16.2%-10.7%··-2.9%·-234.1%183.0%124.9%105.9%92.2%
ROIC -11.8%-20.1%-13.5%··-3.3%·-46.6%-200.8%-80.6%417.0%-551.6%
Liquidité et Solvabilité 5
Métrique Tendance 202520242023202220212020201920182017201620152014
Current Ratio 3.33.32.8··2.9·2.41.41.92.83.6
Quick Ratio 2.22.31.8··2.1·2.01.11.62.43.2
Debt / Equity ·····0.0·0.5-1.4-11.2-0.8-1.2
LT Debt / Equity ·······0.3-1.1-9.4-0.7-1.0
Interest Coverage -7167.1-13113.9-8448.5··-7.5·-12.2-4.7-3.5-4.9-5.2
Efficacité 3
Métrique Tendance 202520242023202220212020201920182017201620152014
Asset Turnover 0.30.30.4··0.7·0.81.10.80.50.3
Inventory Turnover ·····1.0·1.21.81.71.71.2
Receivables Turnover 1.71.82.3··4.5·4.15.57.77.59.4
Par action 5
Métrique Tendance 202520242023202220212020201920182017201620152014
Book Value / Share $1.10$1.18$1.35··$1.60·$0.47$-0.24$-0.03$-0.70$-0.51
Revenue / Share $0.51$0.56$0.75··$1.61·$0.77$0.67$0.61$0.45$0.31
Cash Flow / Share $0.02$-0.08$0.02··$-0.06·$-0.32$-0.12$-0.34$-0.47$-0.42
Cash / Share $0.32$0.29$0.49··$0.48·$0.76$0.27$0.36$0.58$0.68
EPS (TTM) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Taux de croissance 3
Métrique Tendance 202520242023202220212020201920182017201620152014
Revenue YoY -6.6%-25.5%-16.9%-36.7%-5.0%·······
Revenue CAGR 3Y -16.7%-26.8%-20.6%·········
Revenue CAGR 5Y -19.0%···········
Valorisation (TTM) 14
Métrique Tendance 202520242023202220212020201920182017201620152014
Revenue TTM $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Net Income TTM $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
Market Cap $5.81B$4.03B$7.11B··$38.39B·$88.70B$21.74B$16.59B$6.93B$3.42B
Enterprise Value ·····$37.89B·$88.53B$21.76B$16.60B$6.93B$3.41B
P/E -155.1-49.0-116.0-93.13370.0-1956.0-6125.7-697.9-320.8-150.2-45.5-54.4
P/S 27.217.623.2··62.5·387.0120.0127.684.863.1
P/B 12.78.312.9··61.2·582.3-333.9-1831.8-53.7-38.7
P / Tangible Book 13.08.613.417.141.562.6······
P / Cash Flow 863.6-130.01033.9··-1765.4·-936.6-661.9-231.0-81.8-47.3
P / FCF ·····-1745.2·-936.0-661.7-231.0-81.8·
EV / EBITDA ·····-1927.7·-818.0-477.6-252.9-70.6-35.5
EV / FCF ·····-1722.4·-934.2-662.3-231.0-81.8·
EV / Revenue ·····61.7·386.2120.1127.684.862.9
Earnings Yield -0.64%-2.0%-0.86%-1.1%0.03%-0.05%-0.02%-0.14%-0.31%-0.67%-2.2%-1.8%

Période la plus récente à gauche · valeurs nulles affichées comme ·

États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années

16
Métrique 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenu $214M $229M $307M $369M $583M
Marge Brute % 56.6% 35.6% 53.9% · ·
Marge d'exploitation % -23.5% -40.2% -22.0% · ·
Résultat net $-39M $-82M $-59M $-106M $8M
BPA dilué $-0.09 $-0.20 $-0.15 $-0.26 $0.02

Détenteurs institutionnels (13F) 89 déclarants · $64.4M total · Au 30 septembre 2026

17

Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.

Détenteurs 89
Valeur détenue $64.4M
Nouvelles positions 21
Positions clôturées 7
Activité institutionnelle — Q2 2026 vs trimestre précédent
Nouvelles positions Positions clôturées Augmenté Diminué Variation nette des actions
21 (+13 vs T. préc.) 7 (-12 vs T. préc.) 16 (-3 vs T. préc.) 14 (-1 vs T. préc.) +79K

Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.

Institution Valeur Actions % de 13F suivies Type
Sarissa Capital Management LP $26 673 916 1 673 395 41,44% Actions
Kynam Capital Management, LP $8 495 733 532 982 13,20% Actions
MORGAN STANLEY $3 564 456 223 617 5,54% Actions
Waterfront Wealth Inc. $3 183 561 213 949 4,95% Actions
Brooklands Fund Management Ltd $2 741 449 177 325 4,26% Actions
Eversept Partners, LP $2 316 018 145 296 3,60% Actions
MILLENNIUM MANAGEMENT LLC $1 845 980 115 808 2,87% Actions
TWO SIGMA INVESTMENTS, LP $1 602 145 100 511 2,49% Actions
CITADEL ADVISORS LLC $1 520 103 95 364 2,36% Actions
BNP PARIBAS FINANCIAL MARKETS $1 144 699 71 813 1,78% Actions
LCM Capital Management Inc $782 106 60 162 1,22% Actions
RENAISSANCE TECHNOLOGIES LLC $771 002 48 369 1,20% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $765 120 48 000 1,19% Option d'achat
JANE STREET GROUP, LLC $599 790 37 628 0,93% Actions
George Kaiser Family Foundation $593 080 37 207 0,92% Actions
TWO SIGMA ADVISERS, LP $516 265 36 995 0,80% Actions
SEI INVESTMENTS CO $465 628 29 211 0,72% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $462 276 29 001 0,72% Actions
STATE STREET CORP $398 755 25 016 0,62% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $385 748 24 200 0,60% Option de vente
Bleakley Financial Group, LLC $374 670 23 505 0,58% Actions
AMERIPRISE FINANCIAL INC $302 573 18 982 0,47% Actions
State of New Jersey Common Pension Fund D $300 931 18 879 0,47% Actions
CITADEL ADVISORS LLC $299 672 18 800 0,47% Option de vente
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS $292 818 18 370 0,45% Actions
RAYMOND JAMES FINANCIAL INC $289 550 18 165 0,45% Actions
R Squared Ltd $269 992 16 938 0,42% Actions
State of Tennessee, Department of Treasury $239 164 15 004 0,37% Actions
Quadrature Capital Ltd $236 581 14 842 0,37% Actions
Quinn Opportunity Partners LLC $228 022 14 305 0,35% Actions
Cubist Systematic Strategies, LLC $224 390 13 699 0,35% Actions
WELLS FARGO & COMPANY/MN $221 773 13 913 0,34% Actions
EntryPoint Capital, LLC $194 882 12 226 0,30% Actions
Jump Financial, LLC $191 407 12 008 0,30% Actions
GEODE CAPITAL MANAGEMENT, LLC $187 629 11 771 0,29% Actions
OSAIC HOLDINGS, INC. $184 333 11 565 0,29% Actions
NJ State Employees Deferred Compensation Plan $178 542 10 900 0,28% Actions
Verdad Advisers, LP $166 270 10 431 0,26% Actions
CITADEL ADVISORS LLC $164 182 10 300 0,26% Option d'achat
UBS Group AG $160 404 10 063 0,25% Actions
Crossmark Global Holdings, Inc. $146 081 11 237 0,23% Actions
Steward Partners Investment Advisory, LLC $142 025 8 910 0,22% Actions
NEW YORK STATE COMMON RETIREMENT FUND $121 224 7 605 0,19% Actions
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO $92 038 5 774 0,14% Actions
Federation des caisses Desjardins du Quebec $73 518 4 615 0,11% Actions
RHUMBLINE ADVISERS $59 498 3 733 0,09% Actions
NATIONAL BANK OF CANADA /FI/ $40 137 2 518 0,06% Actions
ROYAL BANK OF CANADA $30 000 1 877 0,05% Actions
NewEdge Advisors, LLC $21 471 1 347 0,03% Actions
BlackRock, Inc. $13 677 858 0,02% Actions

Afficher les 89 détenteurs institutionnels →

Activistes et détenteurs de 5%+ 35 participations

18

Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.

Déclarant Déposé Participation Statut Objectif Dépôt
Alexander J Denner, Sarissa Capital Management LP 27 août 2026 6,09% Amendement · SEC
Sarissa Capital Management LP, Alexander J Denner ×3 dépôts 25 mars 2025 8,08% Amendement Campagne de conseil d'administration SEC
28 février 2023 · Dépôt initial · SEC
27 février 2023 · Dépôt initial · SEC
21 février 2023 · Dépôt initial · SEC
OR ×6 dépôts 15 février 2023 · Dépôt initial · SEC
14 février 2023 · Dépôt initial · SEC
10 février 2023 · Dépôt initial · SEC
19 janvier 2023 · Dépôt initial · SEC
16 juin 2022 · Dépôt initial · SEC
Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 dépôts 23 août 2013 · Dépôt initial Investissement passif SEC
Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 dépôts 22 juillet 2013 · Dépôt initial Campagne de conseil d'administration SEC
Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 dépôts 24 août 2011 · Dépôt initial · SEC
OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 dépôts 28 avril 2011 · Dépôt initial · SEC
Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 dépôts 10 décembre 2010 · Dépôt initial · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Initiés de la société 43 initiés · 18 dirigeants · 27 administrateurs

19
Dirigeant Rôle Dernière activité Actions détenues Achats 12m Ventes 12m Net 12m
Aaron Berg President and CEO 26 juin 2026 M 85 648 0 0 $0
Patrick Holt President and CEO 22 janvier 2024 P 314 426 0 0 $0
Karim Mikhail President and CEO 21 février 2023 A 283 507 0 0 $0
John F Thero President and CEO 30 juillet 2021 M 3 252 752 0 0 $0
Peter L. Fishman SVP, CFO 1 août 2026 A 7 619 0 0 $0
Thomas Charles Reilly EVP and CFO 1 juillet 2024 M 94 305 0 0 $0
Michael Wayne Kalb SVP and CFO 29 juillet 2022 M 337 314 0 0 $0
David Paul Keenan EVP, Chief Operating Officer 1 juillet 2026 A 13 470 0 0 $0
Jonathan Provoost EVP, Chief Legal Officer 1 juillet 2026 A 4 624 0 0 $0
Steven B Ketchum EVP, Chief Scientific Officer 1 juillet 2026 A 42 680 0 0 $0
Jason M. Marks EVP,Chief Global Legal Officer 19 août 2022 M 21 917 0 0 $0
Joseph T Kennedy General Counsel 30 juillet 2021 M 317 860 0 0 $0
Mark Salyer Chief Commercial Officer 1 février 2018 A · 0 0 $0
Michael James Farrell VP, Finance 1 février 2016 A 30 190 0 0 $0
Paul Huff Chief Commercial Officer 26 juillet 2012 A 0 0 0 $0
Stuart D Sedlack Senior Vice President 26 juillet 2012 A 0 0 0 $0
Paresh Soni SVP and Head of Development 1 février 2012 A 0 0 0 $0
Frederick W Ahlholm Vice President Finance 1 février 2012 A 0 0 0 $0
Oliver O'Connor Administrateur 18 avril 2026 M 801 0 0 $0
Paul Cohen Administrateur 18 avril 2026 M 836 0 0 $0
Diane E. Sullivan Administrateur 18 avril 2026 M 836 0 0 $0
Louis Sterling III Administrateur 18 avril 2026 M 4 049 0 0 $0
Patrice Eadon Bonfiglio Administrateur 18 avril 2026 M 836 0 0 $0
Keith Horn Administrateur 18 avril 2026 M 836 0 0 $0
Odysseas D Kostas Administrateur 18 avril 2026 M 836 0 0 $0
Mark Dipaolo Administrateur 18 avril 2025 M 401 0 0 $0
Olsen Per Wold Administrateur 10 janvier 2023 M 171 027 0 0 $0
Murray Stewart Administrateur 9 janvier 2023 A · 0 0 $0
Adam Mark Berger Administrateur 20 octobre 2022 A · 0 0 $0
Geraldine Murphy Administrateur 20 octobre 2022 A · 0 0 $0
Alfonso G Zulueta Administrateur 27 juin 2022 A · 0 0 $0
Erin S. Enright Administrateur 27 juin 2022 A · 0 0 $0
Kristine Peterson Administrateur 27 juin 2022 A 0 0 0 $0
Patrick J O'Sullivan Administrateur 27 juin 2022 A · 0 0 $0
Lars Ekman Administrateur 27 juin 2022 A 0 0 0 $0
VAN HEEK G JAN Administrateur 27 juin 2022 A 14 168 0 0 $0
Joseph S Zakrzewski Administrateur 15 décembre 2021 P 196 547 0 0 $0
David M Stack Administrateur 14 juin 2021 A 40 000 0 0 $0
Dr. James I. Healy Administrateur 11 juillet 2016 A 90 000 0 0 $0
GORDON CARL L Administrateur 4 septembre 2012 S 5 700 0 0 $0
Joseph Anderson Administrateur 10 juillet 2012 A 11 683 0 0 $0
David W Feigal Jr Administrateur 12 juillet 2011 A · 0 0 $0
Abingworth LLP Détenteur de 10% 19 avril 2012 S 1 599 168 0 0 $0

Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché

AMRN Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse

21
notation · 7 analystes VENTE
Objectif médian $12.50 +6,0%
0 0,0% Achat fort
0 0,0% Achat
2 28,6% Conserver
3 42,9% Vente
2 28,6% Vente forte

Objectif de cours à 12 mois

2 analystes · 2026-10-24

Objectif moyen $12.50 +6,0%

← En dessous de tous les objectifs Prix actuel $11.79
Bas$12.00 Moyenne$12.50 Haut$13.00

Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur

22

Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.

Ticker Capitalisation Boursière P/E Revenus Année/Année Marge Nette ROE Marge Brute
AMRN $5.81B -155.1 -6.6% -18.2% -8.4% 56.6%
ALKS $4.63B 19.6 -5.2% 16.4% 14.0% ·
PRTA $514M -2.1 -92.8% -2520.6% -63.6% ·

Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets

26

Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.

Votre sélection est enregistrée et vous suit sur tous les tickers.

Source : Dépôt SEC 10-Q le Jul 29, 2026